Open Access

Saikosaponin a attenuates hyperlipidemic pancreatitis in rats via the PPAR‑γ/NF‑κB signaling pathway

  • Authors:
    • Pingping Feng
    • Yanfang Xu
    • Baoyan Tong
    • Xiaoqun Tong
    • Yinyan Bian
    • Shufen Zhao
    • Hongbo Shen
  • View Affiliations

  • Published online on: December 13, 2019     https://doi.org/10.3892/etm.2019.8324
  • Pages: 1203-1212
  • Copyright: © Feng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The therapeutic effect of saikosaponin a (SSa) on hyperlipidemic pancreatitis (HP) is not completely understood. The aim of the present study was to investigate the therapeutic effect and the underlying mechanism of SSa using a rat model of HP. Following successful establishment of the HP rat model, different doses of SSa (low dose group, 10 mg/kg or high dose group, 20 mg/kg) were administrated. Histopathological examination, the wet/dry (W/D) ratio and myeloperoxidase (MPO) activity of the pancreatic tissues were assessed. The lipid, amylase (AMY), lipase and proinflammatory cytokine profiles in serum, as well as the expression of peroxisome proliferator‑activated receptor (PPAR)‑γ and the NF‑κB signaling pathway‑related proteins in pancreatic tissues were evaluated. The results showed that SSa effectively attenuated pancreatic pathological injury and reduced both the W/D ratio and MPO activity compared to the HP model rats. SSa also improved lipid metabolism by significantly decreasing the serum levels of total cholesterol and triglycerides (P<0.05). Following the administration of SSa, the activity of AMY and lipase, as well as the levels of the proinflammatory cytokines tumor necrosis factor‑α, interleukin (IL)‑1β and IL‑6 were reduced, particularly in the high dosage group (P<0.05). Furthermore, SSa activated PPAR‑γ expression and suppressed the NF‑κB signaling pathway in pancreatic tissues. The present study suggested that SSa attenuated HP in rats by increasing lipid metabolism and inhibiting the release of proinflammatory cytokines via the NF‑κB inflammatory pathway. The results from the present study indicated that SSa might be a promising therapeutic agent for the treatment of HP.
View Figures
View References

Related Articles

Journal Cover

February-2020
Volume 19 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Feng P, Xu Y, Tong B, Tong X, Bian Y, Zhao S and Shen H: Saikosaponin a attenuates hyperlipidemic pancreatitis in rats via the PPAR‑γ/NF‑κB signaling pathway. Exp Ther Med 19: 1203-1212, 2020.
APA
Feng, P., Xu, Y., Tong, B., Tong, X., Bian, Y., Zhao, S., & Shen, H. (2020). Saikosaponin a attenuates hyperlipidemic pancreatitis in rats via the PPAR‑γ/NF‑κB signaling pathway. Experimental and Therapeutic Medicine, 19, 1203-1212. https://doi.org/10.3892/etm.2019.8324
MLA
Feng, P., Xu, Y., Tong, B., Tong, X., Bian, Y., Zhao, S., Shen, H."Saikosaponin a attenuates hyperlipidemic pancreatitis in rats via the PPAR‑γ/NF‑κB signaling pathway". Experimental and Therapeutic Medicine 19.2 (2020): 1203-1212.
Chicago
Feng, P., Xu, Y., Tong, B., Tong, X., Bian, Y., Zhao, S., Shen, H."Saikosaponin a attenuates hyperlipidemic pancreatitis in rats via the PPAR‑γ/NF‑κB signaling pathway". Experimental and Therapeutic Medicine 19, no. 2 (2020): 1203-1212. https://doi.org/10.3892/etm.2019.8324